University of Oxford

Apollo Names Industry Veteran Harry Seekings Co-Head of Infrastructure

Retrieved on: 
Friday, February 9, 2024

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that industry veteran Harry Seekings has been named Co-Head of Infrastructure at Apollo, effective March 11, 2024.

Key Points: 
  • NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that industry veteran Harry Seekings has been named Co-Head of Infrastructure at Apollo, effective March 11, 2024.
  • Seekings will work alongside Olivia Wassenaar, Head of Sustainability and Infrastructure.
  • Apollo Co-President Scott Kleinman said, “We are pleased that Harry will join Apollo as Co-Head of Infrastructure.
  • Seekings joins Apollo from InfraRed Capital Partners where he held several leadership roles, including Managing Partner and Head of Infrastructure, overseeing a business line with over 100 professionals across London, New York and Sydney.

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Retrieved on: 
Thursday, February 8, 2024

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom received Breakthrough Therapy designation from the FDA and is under review to become the first medicine approved to treat patients with NASH with liver fibrosis.
  • Approximately 50% of patients treated with resmetirom 100 mg with biopsies at Week 52 showed either NASH resolution or fibrosis improvement.
  • More than 80% of patients with biopsies at Week 52 had either fibrosis reversal or no progression of fibrosis.

Freightos Announces Board of Directors Change

Retrieved on: 
Thursday, February 8, 2024

Carl brings to Freightos' board a wealth of experience and a proven track record in investing in innovative growth companies focused on disruptive technologies.

Key Points: 
  • Carl brings to Freightos' board a wealth of experience and a proven track record in investing in innovative growth companies focused on disruptive technologies.
  • Carl currently serves as a board member at Trieye, a fabless semiconductor company, and at NoTraffic, an AI-powered traffic signal platform developer.
  • Carl, who represents M&G Investments, the largest Freightos investor as of the latest available reports, said, "I believe strongly in Freightos' vision to digitalize the freight industry.
  • Further,  Freightos' contribution to decarbonization through better capacity utilization and better carbon footprint visibility is commendable and aligns with a core mission of M&G.

EQS-News: Dr. Mehmood Khan, CEO of The Hevolution Foundation to speak at Rejuvenation Startup Summit 2024

Retrieved on: 
Thursday, February 8, 2024

Berlin/Germany, February 8, 2024 - We are happy to announce Dr. Mehmood Khan as keynote speaker at the Rejuvenation Startup Summit 2024 in Berlin (May 10-11).

Key Points: 
  • Berlin/Germany, February 8, 2024 - We are happy to announce Dr. Mehmood Khan as keynote speaker at the Rejuvenation Startup Summit 2024 in Berlin (May 10-11).
  • Dr. Khan is CEO of the Hevolution Foundation.
  • Hevolution is also the author of the recently published 'Global Healthspan Report - A New Agenda for Global Health'.
  • Early Bird pricing for the Rejuvenation Startup Summit (May, 10-11) tickets ends soon.

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

Retrieved on: 
Tuesday, February 6, 2024

OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. In addition to grant funding, the award includes drug and business development support from pharma-experienced industry leaders with a track record of bringing therapeutics to market. Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.

Key Points: 
  • OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.
  • Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.
  • The OHC's 2024 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers.
  • Applications directed to other rare, genetic indications with a high unmet need are also of interest.

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

Retrieved on: 
Tuesday, February 6, 2024

OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. In addition to grant funding, the award includes drug and business development support from pharma-experienced industry leaders with a track record of bringing therapeutics to market. Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.

Key Points: 
  • OXFORD, U.K. and CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, U.K. and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking innovative projects for its 2024 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.
  • Awardees have access to the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, which receives support from a partnership between University of Oxford, Oxford Science Enterprises, and University Hospitals in Cleveland, Ohio.
  • The OHC's 2024 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers.
  • Applications directed to other rare, genetic indications with a high unmet need are also of interest.

NinjaOne Secures $231.5M Series C Funding Led by ICONIQ Growth

Retrieved on: 
Tuesday, February 6, 2024

NinjaOne , a leading IT platform for endpoint management, security, and visibility, today announced it raised a $231.5 million Series C funding round led by ICONIQ Growth .

Key Points: 
  • NinjaOne , a leading IT platform for endpoint management, security, and visibility, today announced it raised a $231.5 million Series C funding round led by ICONIQ Growth .
  • With this financing, ICONIQ Growth General Partner Roy Luo has joined NinjaOne’s board of directors.
  • NinjaOne is a founder-led business that has accelerated every year since its first customer, evidenced by a 70+ percent ARR growth rate in 2023.
  • “Under Sal and Chris’s exceptional leadership, NinjaOne has demonstrated impressive product velocity, leading to increased market share, geographic expansion, and customer growth,” said Roy Luo, General Partner at ICONIQ Growth.

$100K on the Line in the Global Artificial Intelligence Championship - Seeking Top AI Models for Mathematical Mastery

Retrieved on: 
Tuesday, February 6, 2024

I can't wait to see how the Global Artificial Intelligence Championship (GAIC) will push the boundaries of AI in mathematics."

Key Points: 
  • I can't wait to see how the Global Artificial Intelligence Championship (GAIC) will push the boundaries of AI in mathematics."
  • AGI Odyssey is empowering interdisciplinary collaboration of mathematics and artificial intelligence by hosting the first Global Artificial Intelligence Championship (GAIC) in March 2024.
  • We invite all AI enthusiasts, professionals, and teams to join the Global Artificial Intelligence Championship.
  • For more details and to register for the Global Artificial Intelligence Championship, please visit: agiodyssey.org

$100K on the Line in the Global Artificial Intelligence Championship - Seeking Top AI Models for Mathematical Mastery

Retrieved on: 
Tuesday, February 6, 2024

I can't wait to see how the Global Artificial Intelligence Championship (GAIC) will push the boundaries of AI in mathematics."

Key Points: 
  • I can't wait to see how the Global Artificial Intelligence Championship (GAIC) will push the boundaries of AI in mathematics."
  • AGI Odyssey is empowering interdisciplinary collaboration of mathematics and artificial intelligence by hosting the first Global Artificial Intelligence Championship (GAIC) in March 2024.
  • We invite all AI enthusiasts, professionals, and teams to join the Global Artificial Intelligence Championship.
  • For more details and to register for the Global Artificial Intelligence Championship, please visit: agiodyssey.org

Global-e Appoints Three Senior Executives - CEO Europe, Chief Technology Officer and Chief Innovation Officer

Retrieved on: 
Monday, February 5, 2024

In addition, Yehiam Shinder will be promoted to the role of Chief Technology Officer, after successful stints as both Global-e's SVP Engineering and VP R&D.

Key Points: 
  • In addition, Yehiam Shinder will be promoted to the role of Chief Technology Officer, after successful stints as both Global-e's SVP Engineering and VP R&D.
  • Yehiam's career, spanning over two decades, has been rooted in technology leadership, innovation, large-scale production systems, and strategic management.
  • Before joining Global-e, he served as the Chief Information Officer at Kaltura, a publicly traded SaaS Video and OTT product company.
  • Furthermore, Global-e is pleased to announce the transition of Eden Zaharoni, a 10+ year veteran of Global-e and current CTO, to a new role of Chief Innovation Officer.